BASF starts up production plant for specialty amines in Ludwigshafen
Global leadership position in specialty amines strengthened.
BASF in Ludwigshafen has started up a world-scale plant for the production of specialty amines. The multi-product plant can manufacture approximately 12,000 metric tons per year of a product range of about 15 amines for different applications. Owing to its high flexibility, the plant can also be used for the production of new specialty amines. The major applications are currently in the construction, automotive, crop protection and pharmaceutical industries. With the new facility, BASF expands its global production network for amines with plants in Ludwigshafen and Schwarzheide in Germany; Antwerp, Belgium; Geismar, North America; and Nanjing, China.
“With the new plant, we are responding to our customers’ growing demand for specialty amines, particularly in Europe,” said Dr Stefan Blank, President, BASF Intermediates division. “We have decades of experience in developing and manufacturing amines and with the current expansion we are extending our global leadership in these versatile intermediates.”
“The special plant structure allows us to react flexibly to changes in the need for the various products. In addition, we can also produce commercial quantities of products from our innovation pipeline here,” said Dr Christoph Wegner, Senior Vice President, heading the regional business unit Amines Europe within BASF’s Intermediates division, and adds: “Being integrated into the BASF Verbund at the Ludwigshafen site also allows us to offer our customers, apart from research, the scale-up services through a pilot plant, all the way to the new multi-product plant.”
With about 200 different amines, BASF has the world’s most diverse portfolio of these chemical intermediates. In addition to alkylamines, alkanolamines and alkoxyalkylamines, the company also offers heterocyclic and aromatic amines as well as specialty amines. The range is completed by an expanding portfolio of chiral amines with high optical and chemical purity. The versatile products have proven their effectiveness above all in the manufacture of crop protection products and pharmaceuticals, as well as in cosmetics, detergents and process chemicals. They are also needed to produce coatings, special plastics, composites and special fibers.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance